NDAINTRAVENOUSPOWDERPriority Review
Approved
Jan 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
Priority Review
CANCIDAS (caspofungin acetate) by Merck & Co. is 12. Approved for fungal infection, invasive candidiasis, candidiasis and 1 more indications. First approved in 2001.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CANCIDAS (caspofungin acetate) is an echinocandin antifungal administered intravenously that treats invasive candidiasis, aspergillosis, and other serious fungal infections. It works by inhibiting fungal cell wall synthesis through beta-glucan synthase inhibition, making it effective against Candida and Aspergillus species in immunocompromised patients.
$0.055MPart D
LOE ApproachingDeclining
As LOE approaches, brand team will shift toward lifecycle management and preparation for generic competition; opportunities exist in hospital formulary defense and retention strategies.
Mechanism of Action
12.1 Mechanism of Action Caspofungin is an echinocandin antifungal drug [see ]. 12.3 Pharmacokinetics Adult and pediatric pharmacokinetic parameters are presented in Table 8. Distribution Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour IV infusions. A…
Worked on CANCIDAS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.